Jefferies on Insmed (INSM): UTHR data 'validates inhaled prostacyclin class in IPF,' INSM's TPIP potl BIC

March 30, 2026 8:29 AM

Jefferies analyst Faisal Khurshid reiterated a Buy rating and $230.00 price target on Insmed (NASDAQ: INSM)The analyst commented, "UTHR reported ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found